...a BLA from ADMA for R1-002, an IV immunoglobulin (IVIG), to treat primary immunodeficiency disease (PIDD...

...with Parkinson's disease (PD) Submit NDA 2H16 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 Primary immunodeficiency disease (PIDD...
...& Johnson (NYSE:JNJ) Sirukumab RA Submit global regulatory apps 3Q16 Green Cross Corp. (KSE:006280) IVIG-SN PIDD...

...million based upon FDA approval of a BLA for RI-002 to treat primary immunodeficiency disease (PIDD...

...PDUFA date 5/1/16 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 polyclonal intravenous immunoglobulin (IVIG) Primary immunodeficiency disease (PIDD...

...target: NA Description: 16% IgG product made from human plasma Indication: Treat primary immunodeficiency disease (PIDD...

...company plans to submit a BLA this year for RI-002 to treat primary immunodeficiency disease (PIDD...

...IBS-D) PDUFA date 2Q15 ADMA Biologics Inc. (NASDAQ:ADMA) RI-002 (intravenous immune globulin) Primary immunodeficiency disease (PIDD...

...Additional data from the open-label, U.S. Phase III ADMA-003 trial in 59 patients with PIDD who...
...standardized high levels of antibodies against respiratory syncytial virus (RSV) Indication: Treat primary immunodeficiency disease (PIDD...

...Top-line data from the open-label, U.S. Phase III ADMA-003 trial in 59 patients with PIDD showed...
...standardized high levels of antibodies against respiratory syncytial virus (RSV) Indication: Treat primary immunodeficiency disease (PIDD...